0001209191-21-026666.txt : 20210414
0001209191-21-026666.hdr.sgml : 20210414
20210414164336
ACCESSION NUMBER: 0001209191-21-026666
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210412
FILED AS OF DATE: 20210414
DATE AS OF CHANGE: 20210414
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lachey Jennifer
CENTRAL INDEX KEY: 0001808322
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39264
FILM NUMBER: 21826142
MAIL ADDRESS:
STREET 1: C/O KEROS THERAPEUTICS, INC.
STREET 2: 99 HAYDEN AVENUE, SUITE 120, BUILDING E
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Keros Therapeutics, Inc.
CENTRAL INDEX KEY: 0001664710
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 99 HAYDEN AVENUE, SUITE 120 (BLD E)
STREET 2: LEDGEMONT TECHNOLOGY CENTER
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 617-513-8774
MAIL ADDRESS:
STREET 1: 99 HAYDEN AVENUE, SUITE 120 (BLD E)
STREET 2: LEDGEMONT TECHNOLOGY CENTER
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-04-12
0
0001664710
Keros Therapeutics, Inc.
KROS
0001808322
Lachey Jennifer
C/O KEROS THERAPEUTICS, INC.
99 HAYDEN AVENUE, SUITE 120, BUILDING E
LEXINGTON
MA
02421
0
1
0
0
Chief Scientific Officer
Common Stock
2021-04-12
4
M
0
5300
0.30
A
76487
D
Common Stock
2021-04-12
4
S
0
998
59.10
D
75489
D
Common Stock
2021-04-12
4
S
0
3473
59.99
D
72016
D
Common Stock
2021-04-12
4
S
0
729
61.08
D
71287
D
Common Stock
2021-04-12
4
S
0
100
61.72
D
71187
D
Employee Stock Option (right to buy)
0.30
2021-04-12
4
M
0
5300
0.00
D
2028-03-25
Common Stock
5300
135005
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.54 to $59.52 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5).
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.55 to $60.43 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.58 to $61.535 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.625 to $61.725 inclusive
Immediately exercisable.
/s/ Keith Regnante, Attorney-in-Fact
2021-04-14